The efficacy of IL-3, SCF, IL-6, and IL-11 in treating thrombocytopenia.
Suppression of normal hematopoiesis is a frequent complication of cancer or its treatment. The basis for dose-intensified cancer therapy in the 1990s was the discovery that hematopoietic growth factors and peripheral blood progenitor cell infusions can ameliorate some of its associated hematologic toxicities. Both granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor accelerate neutrophil recovery after chemotherapy and can mobilize peripheral blood progenitor cells for use in autologous or allogeneic transplantation. Unfortunately, the duration and severity of chemotherapy-induced thrombocytopenia is unaffected by the use of these myeloid growth factors. During the last 5 years, the activities of a variety of potential platelet or megakaryocyte-stimulating factors have been determined in clinical trials. The results of these studies are described.
Maslak
P
P
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Nimer
S D
SD
D006801:Humans; D017370:Interleukin-11 / Q000627:therapeutic use*; D007377:Interleukin-3 / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D019089:Stem Cell Factor / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000188:drug therapy*
D017370:Interleukin-11; D007377:Interleukin-3; D015850:Interleukin-6; D011994:Recombinant Proteins; D019089:Stem Cell Factor